Identical sales without fuel rose 1.0% in the first quarter ended May 23, 2026. Reported EPS reached $1.46, up from $1.29 a year earlier; adjusted EPS was $1.58.

Accenture reported third-quarter fiscal 2026 earnings per share of $3.80, beating the consensus estimate of $3.71. Revenue grew year-over-year, supported by demand in consulting and technology services.

Globant S.A. (GLOB) shares dropped approximately 8.00% in the latest session. The decline was driven primarily by investor concerns around slowing growth in IT services demand.

Acadian Asset Management Inc. (AAMI) shares fell approximately 11.00% in the latest session. The sharp decline appears tied to earnings-related concerns and weaker-than-expected asset flows

SLBT shares declined approximately 19.6% over the past 30 days, closing at $6.28 on June 17, 2026, compared to $7.81 on May 18, 2026. The stock has experienced extreme volatility following its June 15 Nasdaq debut after completing a SPAC merger with Horizon Space Acquisition II Corp.

NovoCure shares are down approximately 16% in premarket trading on June 18, 2026, with the stock quoted near $14.95 against a prior regular-session close of $17.85. The primary catalyst is the announcement that the company's Phase 3 TRIDENT trial in newly diagnosed glioblastoma failed to meet its primary endpoint of demonstrating a statistically significant improvement in overall survival.

Legend Biotech shares are down approximately 11% in premarket trading on June 18, 2026, after closing the prior session at $33.52 on June 17. The primary catalyst is the company's announced pricing of a $226 million underwritten public offering of 7.7 million American Depositary Shares (ADSs) at $29.35 per ADS — a significant discount to the prior closing price.

Accenture shares are down approximately 16.72% in premarket trading on June 18, 2026, with the stock quoted around $130.09 following the prior regular-session close of $156.21. The primary catalyst is a disappointing Q3 FY2026 revenue miss combined with a meaningful cut to full-year revenue guidance, spooking investors already sensitive to IT spending trends.

AVGO shares declined approximately 6.6% over the last 30 days, closing at $392.91 on June 17, 2026, as post-earnings selling pressure offset robust AI demand signals. Q2 FY2026 results delivered record revenue of $22.19 billion (up 48% year-over-year) and AI semiconductor revenue of $10.8 billion (up 143% YoY), yet the stock sold off sharply when full-year AI guidance was reiterated rather than raised.

Accenture is scheduled to report third-quarter fiscal 2026 results before market open on June 18, 2026. Analysts expect earnings per share of approximately $3.71, up about 6% from the year-ago quarter.

Kroger is scheduled to report first quarter 2026 results on June 18, 2026. Analysts project earnings per share of approximately $1.59.

Analysts expect Methode Electronics to report a fiscal fourth-quarter loss amid ongoing industry challenges in automotive and industrial sectors. Consensus estimates point to revenue near prior-year levels with EPS around -$0.19.

National Vision Holdings shares tumbled approximately 7.29% on Wednesday, sliding from a prior close of $17.57 to an intraday low near $16.29. The primary pressure stemmed from persistent post-earnings weakness and investor unease over second-quarter comparable sales tracking in the low-single-digit range following an e-commerce platform disruption.

CarMax (KMX) shares plunged approximately 10.25% on Wednesday, closing near $46.77 after a prior session close of $52.11. The sell-off came despite a strong headline earnings beat — adjusted EPS of $1.31 trounced the $0.95 consensus, and revenue of $8.01 billion exceeded the $7.4 billion estimate.

GENI shares tumbled approximately 11.14% in after-hours trading Wednesday, extending a sharp intraday sell-off from the prior close of $6.87 to a post-market level near $6.11. The primary catalyst was aggressive profit-taking after a blistering 35% rally that carried the stock from roughly $5.30 in late May to above $7.20 by mid-June.

ROOT shares tumbled 13.54% in extended-hours trading on Tuesday, dropping to $49.43 from a prior regular-session close of $57.17. The decline occurred on extremely thin after-hours volume of just 200 shares, amplifying the magnitude of the move.

Regencell Bioscience Holdings shares tumbled approximately 11.54% in after-hours trading on June 17, 2026, extending a multi-day selloff. The primary catalyst is an intensifying legal storm — multiple securities class action lawsuits and a U.

RGNX shares surged 22.80% to close at $8.51 on June 17, 2026, up from the prior session's close of $6.93, marking the stock's strongest single-day gain since the May 14 selloff. Primary catalyst: Anticipation of the imminent $100 million AbbVie milestone payment , triggered upon first patient dosing in the Phase IIb/III NAAVIGATE diabetic retinopathy study, which management guided would occur in Q2 2026 — a quarter that ends in just 13 days.